Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA

Vera Therapeutics

NovaPharmaNews editorial coverage mentioning Vera Therapeutics — regulatory, clinical, and market analysis.

Website Investor relations
4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
Status
Public
HQ
4539 Metropolitan Ct, Frederick, Maryland 21704, US
Founded
2018
Employees
9
Programs
25
Drugs
32
Patents
140
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Vera Therapeutics — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning Vera Therapeutics — regulatory, clinical, and market analysis.

All News Analysis

1 articles

New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
High impact AnalysisJun 2, 2026

New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights

9 min

A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.